BCHE and Alzheimer disease: Compounds 230 and 235 inhibited the butyrylcholinesterase (BChE) more potently than neostigmine, suggesting that they may serve as lead compounds for the development of novel BChE inhibitors and candidate lead compounds for the prevention or treatment of Alzheimer’s disease [55].